If you have Waldenstrom’s Macroglobulinemia (WM) or you are a caregiver of a patient with WM, you can help by completing the surveys.
Lymphoma Canada, in partnership with the Canadian Organization… Continue reading
April 4, 2016 – We are pleased to announce that Health Canada has approved Ibrutinib for WM patients in Canada. The decision was based on sponsored study data. Information has yet to be released on the funding of the… Continue reading
According to Steven P. Treon, MD, PhD, mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström’s macroglobulinemia (WM).
“Linking biological data to clinical data is beginning to identify clinically distinct subgroups… Continue reading
Progress in the Treatment of Waldenstrom’s Macroglobulinemia
Wednesday, September 2, 2015
1:30 – 2:30 PM Eastern Time
Participate online or over the phone
Article from the New England Journal of Medicine
Many of you have had questions about the pathway that led to the FDA approval of Imbruvica for WM. I wanted to share with you the attached video of Dr Treon’s interview on this historic approval which I hope… Continue reading